An observational study in Infantile Hemangioma (IH), sponsored by West China Hospital. Recruiting at 3 sites in China. Open to participants aged 0 Days to 7 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by West China Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hemangioma, Capillary with a site in China — 6 open to participants now, 7 under way, 1 of them phase 3. Hemangioma, Capillary · China.
Among the 12 studies in Hemangioma, Capillary with a site in China, this one is one of 2 that started in 2024, is one of 7 observational ones, and was the 11th registered.
35 studies on the registry are indexed under Hemangioma, Capillary; 6 are open to participants now.
Browse Hemangioma, Capillary studies →6 of the 12 studies in Hemangioma, Capillary with a site in China are open now. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 0 mo–12 mo
West China Hospital · Sites in China
Ages up to 6
West China Hospital · Sites in China
Ages 6 mo–60 mo
West China Hospital · Sites in China
Ages 0 mo–12 mo
West China Hospital · Sites in China
Ages 0–10
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 3 Hemangioma, Capillary studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 0 Days to 7 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 3 · Phase 4 1
First in 2013; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3 is below the median of 150 across 14 observational studies indexed under Hemangioma, Capillary.
Median enrollment 168 across the 5 interventional studies, 150 across the 7 observational. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 12 have an industry lead sponsor. The 5 most frequent:
West China Hospital is the lead sponsor of 503 studies on the registry; 247 are open to participants now.
West China Hospital has 8 studies filed under Hemangioma, Capillary — fewer than ten, so there is no comparison to draw.
3 of the studies in Hemangioma, Capillary with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07938710West China HospitalIncidence and Clinical Features of PHACE Syndrome | 2027-03-31 |
| NCT07616323West China HospitalScreening LUMBAR Syndrome in Infants With Infantile Hemangiomas | 2027-06-30 |
| NCT07938723West China HospitalThe Incidence and Clinical Characteristics of Infantile Hemangiomas | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 12 studies in Hemangioma, Capillary with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will follow babies born at three hospitals in China during their first year of life. The study will measure how often babies are diagnosed with infantile hemangioma, a growth of blood vessels in the skin that often appears in early infancy. The study team will record the age at diagnosis, the location and size of the hemangioma, and its clinical appearance. Babies with and without a hemangioma at the first examination can participate. Clinical care will follow usual practice.
This is a prospective, multicenter observational birth cohort study. At each of three participating hospitals, live-born infants will be screened using delivery records. All eligible infants will be invited consecutively during the recruitment period. Enrollment and a baseline skin assessment will take place within seven days of birth after a parent or legal guardian provides written informed consent.
Follow-up assessments are planned at 1 and 3 months of chronological age. The study team will also capture diagnoses documented between scheduled assessments. Trained study clinicians will use the same clinical criteria at all centers, with specialist review of uncertain cases. Suspected precursor lesions will be recorded at baseline and followed to establish the diagnosis. Clinicians will distinguish infantile hemangiomas from congenital hemangiomas and vascular malformations.
The primary analysis will include infants with an assessable baseline examination and without definite cutaneous infantile hemangioma at that examination. Secondary analyses will report the baseline prevalence and the overall proportion diagnosed by 3 months of age, including infants diagnosed at baseline. Clinical characteristics will be recorded at the first confirmed diagnosis. When several lesions are present, the lesion with the greatest documented diameter at diagnosis will be the index lesion for site, depth, morphology, and size.
Post-baseline cumulative incidence will be estimated on the chronological age scale with entry at the baseline examination and reported with a 95% confidence interval. Death before diagnosis will be treated as a competing event. Infants lost to follow-up will be censored at the last assessment at which their disease status could be determined. Clinical management will follow usual care.
Live-born infants delivered at any of the three participating hospitals during the recruitment period. Eligible infants will be invited consecutively from hospital delivery records, regardless of gestational age, sex, or baseline infantile hemangioma status.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live-born infants enrolled within seven days of birth at any of the three participating hospitals and followed through 3 months of chronological age.
Post-baseline Cumulative Incidence of Cutaneous Infantile Hemangioma by 3 Months of Age
Estimated percentage of infants with an assessable baseline examination and no definite cutaneous infantile hemangioma at that examination who receive a first clinician-confirmed diagnosis by 3 months of age. Each affected infant is counted once. Death before diagnosis is treated as a competing event. Infants lost to follow-up are censored at the last assessment with ascertainable disease status.
Time frame: From the baseline newborn assessment (within 7 days of birth) through 3months of chronological age.
Prevalence of Definite Cutaneous Infantile Hemangioma at Baseline
Percentage of infants with an assessable baseline examination who have definite cutaneous infantile hemangioma at that examinatio
Time frame: Baseline assessment, within 7 days of birth.
Anatomic Site of the Index Lesion
Number and percentage of affected infants by the anatomic site of the index lesion (head and neck, trunk, extremities, diaper area, or other)
Time frame: At first confirmed diagnosis, through 3 months of age.
Plan to share: Undecided
Started Jun 2024 (actual). Primary completion is estimated for Jun 2027, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.